Available Brands
Did you find this information helpful?
Author Details
Written By
Vishishta
M.Sc Microbiology

Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 19 Oct 2026 | 09:53 AM (IST)

Want to know more?
Read Our Editorial Policy
Quick Summary
TELMISARTAN,METOPROLOL
Last updated on 19 Oct 2026 | 09:53 AM (IST)
TELMISARTAN,METOPROLOL
Molecule Overview
This is a fixed combination of telmisartan and metoprolol, two well-established medicines used together to treat high blood pressure (hypertension). It combines an angiotensin receptor blocker (ARB) with a beta-blocker, two complementary blood-pressure-lowering mechanisms, in a single tablet. It is a prescription-only medicine, widely used in India and similar markets.
Medical Classification
Therapeutic Class: Antihypertensive combination therapy.
Pharmacological Class: Angiotensin II receptor blocker (telmisartan) plus selective beta-1 blocker (metoprolol).
Drug Family: Combination cardiovascular therapy.
ATC Classification: C07FB (Beta blocking agents and other antihypertensives) — specific combination code varies by region.
Conditions Treated
Approved/established use: Essential hypertension in adults, particularly when blood pressure is not adequately controlled on monotherapy with either component alone, and in patients with hypertension who also have stable coronary artery disease.
Commonly used for: Patients with moderate to severe hypertension needing more than one blood-pressure-lowering mechanism, including those with coexisting coronary artery disease.
Off-label use (only under medical guidance): Not typically used off-label; both individual components have broader established cardiovascular uses that may factor into why this combination is chosen for a given patient.
Available Strengths & Dosage Forms
Oral tablets (extended-release): commonly telmisartan 40 mg combined with metoprolol succinate (extended-release) 25 mg or 50 mg.
How the Molecule Works
Telmisartan blocks angiotensin II, a hormone that narrows blood vessels and raises blood pressure, by blocking its receptor — this relaxes blood vessels and lowers blood pressure. Metoprolol blocks beta-1 receptors, primarily in the heart, slowing the heart rate and reducing the force of heart contractions, which also lowers blood pressure and reduces the heart's workload. Combined, the two medicines lower blood pressure through complementary mechanisms, often achieving better control than either alone.
Dosage & Administration
Standard dose: Telmisartan 40 mg/metoprolol succinate (extended-release) 25 mg or 50 mg, taken orally once daily, with the specific strength chosen based on blood pressure response and tolerability.
Condition-wise dose: Dose selection and any escalation between the two available strengths is guided by the treating doctor based on blood pressure readings over follow-up visits.
Route: Oral, once daily, generally taken at a consistent time each day; extended-release formulations should be swallowed whole and not crushed or chewed.
Missed dose: Take as soon as remembered unless close to the next dose; don't double up.
Overdose: Can cause excessive lowering of blood pressure and heart rate (hypotension, bradycardia); requires urgent medical attention.
Side Effects
Common: Dizziness, fatigue, and slow heart rate (linked to the metoprolol component).
Serious: Significant bradycardia (very slow heart rate), symptomatic low blood pressure, and, rarely, worsening of heart failure symptoms if present.
Emergency symptoms: Fainting, severe dizziness, very slow or irregular heartbeat, or chest pain.
Recovery advice: Mild dizziness or fatigue often improves as the body adjusts; any new or worsening shortness of breath, significant fatigue, or a notably slow pulse should be reported to the treating doctor.
Warnings & Precautions
Pregnancy: Contraindicated; angiotensin receptor blockers like telmisartan can cause fetal harm, particularly in the second and third trimesters.
Breastfeeding: Discussed with the treating doctor given presence of both components in breast milk to varying degrees.
Liver disease: Used with caution; both components are metabolised by the liver, and dose adjustment may be needed in significant impairment.
Kidney disease: Used with routine monitoring; telmisartan requires caution in significant renal artery stenosis or severe impairment.
Elderly: Commonly used in this age group; monitored for blood pressure and heart rate response, and for increased sensitivity to blood-pressure-lowering effects.
Children: Not established for use in children; an adult hypertension medicine.
Drug Interactions
Other beta-blockers or rate-lowering medicines (e.g., verapamil, diltiazem, digoxin): combining can increase the risk of excessive heart rate or blood pressure lowering.
Potassium-sparing diuretics or potassium supplements: telmisartan can increase potassium levels, so combined use requires monitoring.
NSAIDs: may reduce the blood-pressure-lowering effect of both components when used regularly, and may also affect kidney function when combined with telmisartan.
Lithium: telmisartan can increase lithium levels, requiring closer monitoring if combined.
Monitoring Requirements
Blood pressure checks regularly to assess control.
Heart rate monitoring, particularly when starting or adjusting the dose.
Serum potassium and kidney function periodically, given telmisartan's effects on these parameters.
Pregnancy testing before starting in women of reproductive potential, given the contraindication.
Alternative Molecules
Telmisartan or metoprolol used as separate individual tablets, allowing more flexible dose titration; other ARB/beta-blocker or ARB/calcium-channel-blocker combinations depending on individual patient factors.
Combination Therapies
This is itself a fixed combination of two blood-pressure medicines; additional antihypertensive agents (e.g., diuretics, calcium channel blockers) may be added by the treating doctor if blood pressure remains uncontrolled on this combination alone.
Hypertension Medicines
Angiotensin Receptor Blockers (ARBs)
Beta-Blockers
FAQs
Q1.
It's used to treat high blood pressure, particularly when a single medicine alone doesn't provide adequate control, including in patients with coexisting coronary artery disease.
Q2.
The two medicines lower blood pressure through different, complementary mechanisms — relaxing blood vessels (telmisartan) and slowing/easing the heart's workload (metoprolol) — which together can achieve better blood pressure control than either alone.
Q3.
No, it's contraindicated in pregnancy, as telmisartan (an ARB) can cause fetal harm, particularly later in pregnancy.
Q4.
No, stopping beta-blocker-containing medicines abruptly can cause a rebound increase in heart rate and blood pressure; any change should be guided by the treating doctor.
Q5.
Regular blood pressure and heart rate checks, along with periodic kidney function and potassium level monitoring.
Disclaimer
The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.






